Focus: ICU Medical is a medical device manufacturer specializing in disposable products for cardiovascular and critical care applications, based in San Clemente, CA. The company operates in the biotechnology segment with a focus on sterile, single-use clinical solutions.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Growing — net +7 jobs in 30d
99 jobs added vs 92 removed. Steady team buildout.
ICU Medical is a stable, commercial-focused device company best suited for supply chain, manufacturing, and sales professionals seeking stable employment, but offers limited scientific innovation opportunities for R&D-oriented pharma careers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
IV electrolyte formulation for cardiac support; approaching loss of exclusivity suggests revenue erosion imminent.
Help build intelligence for ICU Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ICU Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Parenteral nutrition product for clinical use; exclusivity approaching limits future revenue potential.
Specialty saline formulation for invasive hemodynamic assessment; approaching LOE constrains market position.
High-concentration amino acid formulation; exclusivity loss anticipated, standard generic competition expected.
Lower-concentration amino acid product; approaching LOE creates margin pressure in nutritional category.
Mid-range amino acid formulation with electrolytes; exclusivity approaching signals portfolio vulnerability.
Heart-failure focused amino acid formulation already post-exclusivity; generic competition active and revenue declining.
High-concentration formulation with electrolytes; exclusivity approaching creates near-term revenue risk.
pH-optimized amino acid formulation; approaching LOE limits differentiation and pricing power.
Lower-concentration formulation with minerals; exclusivity approaching narrows commercial opportunity.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo